Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;37(Suppl 4):S82-S88.
doi: 10.12788/fp.0033.

Integrating Germline Genetics Into Precision Oncology Practice in the Veterans Health Administration: Challenges and Opportunities

Affiliations

Integrating Germline Genetics Into Precision Oncology Practice in the Veterans Health Administration: Challenges and Opportunities

Maren T Scheuner et al. Fed Pract. 2020 Aug.

Abstract

Objectives: The advent of germline testing as a standard-of-care practice for certain tumor types and patients presents unique opportunities and challenges for the field of precision oncology. This article describes strategies to address workforce capacity, organizational structure, and genetics education needs within the US Department of Veterans Affairs (VA) with the expectation that these approaches may be applicable to other health care systems.

Observations: Germline information can have health, reproductive, and psychosocial implications for veterans and their family members, which can pose challenges when delivering germline information in the setting of cancer care. Additional challenges include the complexity inherent in the interpretation of germline information, the national shortage of genetics professionals, limited awareness and knowledge about genetic principles among many clinicians, and organizational barriers, such as the inability to order genetic tests and receive results in the electronic health record. These challenges demand thoughtful implementation planning at the health care system level to develop sustainable strategies for the delivery of high-quality genetic services in precision oncology practice.

Conclusions: The VA is uniquely positioned to address the integration of germline genetic testing into precision oncology practice due to its outsized role in treating veterans with cancer, training the health care workforce, and developing, testing, and implementing innovative models of clinical care.

PubMed Disclaimer

Conflict of interest statement

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Figures

FIGURE
FIGURE
Genetic Consultation: A Shared Decision-Making Process Genetic testing for hereditary cancer syndromes typically is offered in the setting of genetic consultation comprised of evaluation and counseling processes. Genetic evaluation for a hereditary condition is a process informed by comprehensive review and synthesis of medical history, social history, exposure history, family history, physical examination, and results from pathology reports, laboratory tests, imaging, procedures, and consultations. Genetic evaluation results in a differential diagnosis, including both genetic and nongenetic diagnoses. If indicated, a genetic testing strategy is recommended to further inform the differential diagnosis or risk assessment. Clinical decision making based on the genetic diagnosis may include recommendations for additional diagnostic evaluation (eg, imaging or procedures), disease management and prevention, reproductive options, lifestyle changes, and longitudinal follow-up. Genetic counseling is a communication process that facilitates patient decision making surrounding the genetic evaluation. Patient preferences, values, family dynamics, educational level, and cultural norms are considered and inform the patient’s perception and knowledge of their genetic diagnosis or risk, and self-efficacy to cope with and make decisions based on this information.

Similar articles

Cited by

References

    1. Zullig LL, Sims KJ, McNeil R, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System: 2010 update. Mil Med. 2017;182(7):e1883–e1891. doi: 10.7205/MILMED-D-16-00371. - DOI - PMC - PubMed
    1. Li MM, Chao E, Esplin ED, et al. Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG) Genet Med. 2020;22(7):1142–1148. doi: 10.1038/s41436-020-0783-8. - DOI - PubMed
    1. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. doi: 10.1186/s13073-019-0703-1. Published 2020 Jan 14. - DOI - PMC - PubMed
    1. Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing [published correction appears in JAMA. 2018 Dec 11;320(22):2381] JAMA. 2017;318(9):825–835. doi: 10.1001/jama.2017.11137. - DOI - PMC - PubMed
    1. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708. doi: 10.1056/NEJMoa1506859. - DOI - PMC - PubMed

LinkOut - more resources